Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Invested Capital (2016 - 2025)

Historic Invested Capital for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $23.3 million.

  • Aytu Biopharma's Invested Capital fell 3307.07% to $23.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $23.3 million, marking a year-over-year decrease of 3307.07%. This contributed to the annual value of $28.0 million for FY2025, which is 691.44% down from last year.
  • Per Aytu Biopharma's latest filing, its Invested Capital stood at $23.3 million for Q4 2025, which was down 3307.07% from $38.0 million recorded in Q3 2025.
  • Aytu Biopharma's 5-year Invested Capital high stood at $153.8 million for Q2 2021, and its period low was $23.3 million during Q4 2025.
  • Over the past 5 years, Aytu Biopharma's median Invested Capital value was $46.5 million (recorded in 2023), while the average stood at $63.4 million.
  • As far as peak fluctuations go, Aytu Biopharma's Invested Capital surged by 6158.17% in 2021, and later plummeted by 6145.08% in 2022.
  • Over the past 5 years, Aytu Biopharma's Invested Capital (Quarter) stood at $121.8 million in 2021, then plummeted by 50.06% to $60.8 million in 2022, then tumbled by 44.29% to $33.9 million in 2023, then grew by 2.65% to $34.8 million in 2024, then plummeted by 33.07% to $23.3 million in 2025.
  • Its last three reported values are $23.3 million in Q4 2025, $38.0 million for Q3 2025, and $28.0 million during Q2 2025.